1. P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (5th April 2022) Authors: Popat, R; Usmani, S; Garfall, A; van de Donk, N; Nahi, H; San-Miguel, J; Oriol, A; Nooka, A; Martin, T; Rosinol, L; Chari, A; Karlin, L; Benboubker, L; Mateos, M; Bahlis, N; Moreau, P; Besemer, B; Martínez-López, J; Sidana, S; Pei, L Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗